Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.30 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.30 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952614 | 0.83 | HPGD (0.35) | ERN1 | |
| SCHEMBL9952114 | 0.80 | MEP1A (0.33) | ERN1MEP1AMEP1B | |
| SCHEMBL9953135 | 0.80 | IMPDH2 (0.36) | ERN1 | |
| SCHEMBL9953163 | 0.78 | IMPDH2 (0.37) | MEP1B | |
| SCHEMBL9952884 | 0.75 | LMNA (0.33) | — | |
| SCHEMBL21812007 | 0.74 | IDO1 (0.37) | ERN1 | |
| SCHEMBL1905388 | 0.73 | ERCC1 (0.35) | ERN1 | |
| SCHEMBL9953041 | 0.72 | HPGD (0.42) | ERN1 | |
| SCHEMBL1578296 | 0.71 | TSHR (0.41) | ERN1 | |
| SCHEMBL15054235 | 0.70 | MEP1B (0.44) | MEP1AMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021158891-A1 | SALTS AND SOLID FORMS AND PROCESSES OF PREPARING A PI3K INHIBITOR | INCYTE CORPORATION (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3262046-A1 | SALTS OF PI3K INHIBITOR AND PROCESSES FOR THEIR PREPARATION | Incyte Corporation (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138363-A1 | SALTS OF PI3K INHIBITOR AND PROCESSES FOR THEIR PREPARATION | INCYTE CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-2961410-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013151930-A1 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |